Hims & Hers Jumps 48.7% on Novo Nordisk Patent Settlement and Partnership
SPSM ETF holds 0.60% in Hims & Hers Health, whose shares jumped 48.67% in premarket trading after settling a patent lawsuit with Novo Nordisk and securing a weight-loss drug partnership. Hims & Hers reported Q4 revenue of $617.82M (est. $619.22M) and Q1 revenue guidance of $600M–$625M (est. $653.12M).
1. Hims & Hers Stock Surge
Shares of Hims & Hers Health rose 48.67% in premarket trading after resolving a patent dispute with Novo Nordisk and securing rights to sell its weight-loss drug via Hims & Hers’ telehealth platform, marking a significant catalyst for the stock.
2. Q4 Results and Guidance
The company reported Q4 revenue of $617.82 million versus analyst estimates of $619.22 million, beat EPS estimates with $0.08 per share, and offered Q1 revenue guidance of $600 million to $625 million below the $653.12 million consensus, while forecasting fiscal 2026 sales of $2.7 billion to $2.9 billion.
3. ETF Exposure and Impact
SPDR Portfolio S&P 600 Small Cap ETF (SPSM) holds a 0.60% position in Hims & Hers, meaning the sharp share movement and mixed guidance could have a modest impact on overall ETF performance given the small allocation.